Oric Pharmaceuticals
Chris Weber is a Senior Scientist at ORIC Pharmaceuticals Inc. since November 2020, specializing in small molecule drug discovery in oncology and leading a group focused on new target conception, validation, and high-throughput screening. Previously, Chris held the position of Postdoctoral Research Fellow in the Gerald Crabtree Lab at Stanford University from September 2014 to October 2020, where notable contributions included the development of mESC lines using CRISPR/Cas9 for studying chromatin remodeling complexes. Chris's academic journey includes a Ph.D. in Molecular and Cellular Biology from the University of Washington and significant research experience at institutions such as Fred Hutchinson Cancer Research Center and the University of California, San Francisco, where foundational research was conducted in chromatin genomics and the genetic basis of hearing impairment, respectively.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.